Modified Quadruplet Regimen Effective in Older Myeloma Patients
Modifying the quadruplet regimen of isatuximab, bortezomib, lenalidomide, and dexamethasone could allow older, frail patients with transplant-ineligible multiple myeloma to benefit from the therapy. The